Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT03184519 |
Date of registration:
|
09/06/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.
hyperPOC |
Scientific title:
|
Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy After In-vitro Fertilization and Embryo Transfer. |
Date of first enrolment:
|
June 19, 2017 |
Target sample size:
|
156 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03184519 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Spain
| | | | | | | |
Contacts
|
Name:
|
Ernesto Bosch, MDPhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
IVIRMA VALENCIA |
| | |
Key inclusion & exclusion criteria
|
Inclusion criteria:
- Written informed consent
- Patients undergoing their first or second IVF-ET cycle
- Age 18-45 years
- Use of Ovitrelle for final follicular maturation and luteinization
- Fresh or Frozen day-5 blastocysts transrer (Autologus or Egg donation)
Exclusion criteria:
- Gestational surrogacy (patient's eggs used for pregnancy in a surrogate mother)
- Canceled IVF cycles
- GnRH agonist triggering cycles in the case of fresh ET.
Age minimum:
18 Years
Age maximum:
45 Years
Gender:
Female
|
Health Condition(s) or Problem(s) studied
|
Pregnancy Test
|
Intervention(s)
|
Diagnostic Test: Pregnancy test
|
Primary Outcome(s)
|
Number of Participants With Early Detection of Pregnancy
[Time Frame: One month]
|
Secondary ID(s)
|
1701-VLC-011-EB
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|